Condition: Depressive Disorder, Treatment-Resistant · Sponsor: Janssen Korea, Ltd., Korea
The purpose of this study is to evaluate how well esketamine nasal spray works in improving depressive symptoms in participants with treatment resistant depression (TRD). This will be assessed by the change from baseline in the Hamilton depression rating scale (HAM-D; 17-item) total score from Day 1 (baseline) to the end of the 4-week treatment phase (Day 28).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| Cha Ilsan Medical Center | Goyang Si Gyeonggi Do, South Korea | Recruiting |
| Wonkwang University Hospital | Iksan, South Korea | Recruiting |
| Kangbuk Samsung Hospital | Seoul, South Korea | Recruiting |
| Asan Medical Center | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
| Kyung Hee University Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07053345